David McKinley actually said...
Policies like referencing pricing and government price-settings will effectively turn our biopharma industry to a risk-averse, think-inside-the-box-rather-than-outside-the-box commodity industry.
Context
McKinley warns that certain policies could harm innovation in the biopharma sector.
05/03/2021